Navigation Links
Hematologic in Medical News
5- and 10-year survival continues to improve for US children with hematologic malignancies
5- and 10-year survival rates continue to improve for children under the age of 15 who are diagnosed with acute lymphoblastic leukemia (ALL), acute non-lymphoblastic leukemia, or non-Hodgkin lymphoma (NHL) in the United States, researchers report in the September 9 online issue of the Journal of ......rall survival and safety. Dr. Kenneth Anderson, Chief, Division of hematologic Neoplasia, Dana-Farber Cancer Institute, commented, "Perifosine holds great...ncurable but treatable disease. Multiple myeloma is the second most-common hematologic cancer, representing 1% of all cancer diagnoses and 2% of all cancer deaths...
Millennium Pharmaceuticals Inc./Lymphoma Research Foundation funds lymphoma research
...targets. We are delighted that Dr. Fu has chosen MCL as the focus of his Clinical Career Development Project," stated Michael Williams, MD, Director, hematologic Malignancy Program - University of Virginia and Chair of LRF's Mantle Cell Consortium The 3-year Clinical Investigator Career Development Award is ...Sunesis Pharmaceuticals Appoints Helen S. Kim to Board of Directors
...cals Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of hematologic and solid cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vore......t ovarian cancer or AIDS-related Kaposi's sarcoma, hematologic toxicity (based on platelet count or absolute neut...OXIL In patients with multiple myeloma, hematologic toxicity (based on platelet count, absolute neutro...toxicity of other anticancer therapies, especially hematologic toxicities, when used in combination with other th...
Six Researchers to Receive Prestigious Awards from the American Society of Hematology
...e world's largest professional society of blood specialists, will honor six scientists who have made significant contributions to the understanding of hematologic diseases. These awards, including the newly created Ernest Beutler Lecture and Prize, will be presented at the 51st ASH Annual Meeting taking place De...Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec
...mmercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that it has received a $1.5 million milestone paym...mmercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development org...... FT1050, a small molecule SCM designed to increase hematopoietic stem cell number and function in dual umbilical cord blood transplant recipients with hematologic malignancies. In addition, Fate Therapeutics and Stemgent have formed an alliance - CATALYST - a collaborative program to provide its members with fi...
NCI Renews Mayo Clinic Cancer Center Support Grant, Extends Comprehensive Status
... faculty across all three sites are organized into programs that focus on 12 key cancer research themes. They include Women's Cancers, Neuro-Oncology, hematologic (bloodborne) Malignancies, Gene and Virus Therapy, Developmental Therapeutics, Genetic Epidemiology and Risk Assessment, Immunology and Immunotherapy,...NCI renews Mayo Clinic Cancer Center support grant, extends comprehensive status
... faculty across all three sites are organized into programs that focus on 12 key cancer research themes. They include Women's Cancers, Neuro-Oncology, hematologic (bloodborne) Malignancies, Gene and Virus Therapy, Developmental Therapeutics, Genetic Epidemiology and Risk Assessment, Immunology and Immunotherapy,...Hematologic in Medical Technology
- Results Presented at ASH Annual Meeting-
SAN FRANCISCO, Dec. 6 /PRNewswire-FirstCall/ -- Sanofi-aventis today announced results of a randomized phase III study presented at the 50th Annual Meeting of the American Society of Hematology. The study in adult patients with hematological mali...
...data to date suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Results to date suggest that hematologic events are common but manageable. Kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) are less frequent and less severe than is common...
...th. More than 200 patients have been treated with brostallicin in single-agent and combination studies. Brostallicin had predictable and predominantly hematologic toxicities. Activity was demonstrated in a number of solid tumor types. A phase II study of brostallicin in relapsed/refractory soft tissue sarcoma me...
...openia, have been infrequently reported with SIMPONI in clinical trials. Discontinuation of SIMPONI should be considered in patients with significant hematologic abnormalities. The concurrent administration of TNF-antagonists with anakinra or abatacept is not recommended. Concurrent administration has b...
... Loaie M. El-Helw of the Weston Park Hospital, Sheffield UK. The review focuses on the impressive preclinical anti-tumor activity demonstrated in hematologic cancers over standard anthracyclines and the rational design modifications to the chemical compound believed to be responsible for enhanced DNA damage...
...ble proteasome inhibitors being developed by Proteolix for the treatment of hematologic malignancies and solid tumors. Data from the Phase 2 clinical trial ...se 2 clinical trials, carfilzomib has demonstrated single-agent activity in hematologic malignancies and solid tumors, including multiple myeloma, Waldenstrom's ma...
... being developed by Proteolix for the treatment of hematologic malignancies and solid tumors. "In these cl...rfilzomib as a promising new protease inhibitor in hematologic and solid tumor malignancies. Carfilzomib is well...filzomib has demonstrated single-agent activity in hematologic malignancies and solid tumors, including multiple ...
...ropathy-sparing alternative to FOLFOX (p<0.0019). With regard to hematologic toxicities, thrombocytopenia and neutropenia were more frequent and severe ...than 1,100 patients have received picoplatin. To date, results suggest that hematologic events are severe but manageable. Kidney toxicity (nephrotoxicity) and nerv...
Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
HDAC Inhibitor MGCD0103 Demonstrates substantial Response Rate in Two Clinical Trials Clinical Data Presented on Pilot Pharmacokinetic Study of Oral Azacitidine Exelixis Reports Comprehensive XL880 Phase I Data At ASCO Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 a...Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
GERMANTOWN, Md., June 13, 2007 /PRNewswire-FirstCall/ -- Avalon Pharmaceuticals, Inc. , today announced that it is will provide an update on the Phase I clinical trial of AVN944 in hematologic malignancies on Tuesday, June 19, 2007, after the close of the U.S. financial markets. The Company will a......data to date suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Results to date suggest that hematologic events are common but manageable. Kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) are less frequent and less severe than is common...
...th. More than 200 patients have been treated with brostallicin in single-agent and combination studies. Brostallicin had predictable and predominantly hematologic toxicities. Activity was demonstrated in a number of solid tumor types. A phase II study of brostallicin in relapsed/refractory soft tissue sarcoma me...
...openia, have been infrequently reported with SIMPONI in clinical trials. Discontinuation of SIMPONI should be considered in patients with significant hematologic abnormalities. The concurrent administration of TNF-antagonists with anakinra or abatacept is not recommended. Concurrent administration has b...
... Loaie M. El-Helw of the Weston Park Hospital, Sheffield UK. The review focuses on the impressive preclinical anti-tumor activity demonstrated in hematologic cancers over standard anthracyclines and the rational design modifications to the chemical compound believed to be responsible for enhanced DNA damage...
...ble proteasome inhibitors being developed by Proteolix for the treatment of hematologic malignancies and solid tumors. Data from the Phase 2 clinical trial ...se 2 clinical trials, carfilzomib has demonstrated single-agent activity in hematologic malignancies and solid tumors, including multiple myeloma, Waldenstrom's ma...
... being developed by Proteolix for the treatment of hematologic malignancies and solid tumors. "In these cl...rfilzomib as a promising new protease inhibitor in hematologic and solid tumor malignancies. Carfilzomib is well...filzomib has demonstrated single-agent activity in hematologic malignancies and solid tumors, including multiple ...
...ropathy-sparing alternative to FOLFOX (p<0.0019). With regard to hematologic toxicities, thrombocytopenia and neutropenia were more frequent and severe ...than 1,100 patients have received picoplatin. To date, results suggest that hematologic events are severe but manageable. Kidney toxicity (nephrotoxicity) and nerv...
Hematologic in Medical Products
Pocket Guide to Chemotherapy Protocols, 2nd Edition
Features:... Completely revised and updated Contains combination as well as selected single-agent regimens for solid tumors and hematologic malignancies The regimens selected are based on the published literature and are used in clinical practice in the medical oncology community ...Company:Skyscape, Inc.
Hematologic in Medical Dictionary
...ew importance to adult ... Hemoglobin E-beta thalassemia is seen with increasing frequency and poses a ... Testing for α- thalassemia includes: hematologic testing of red blood cell ... Alpha- thalassemia is usually inherited in an autosomal recessive manner. ... Thalassemia is an inherited d...
... splenomegaly is usually defined as a spleen ex ... study evaluating splenomegaly in 2056 patients who ... massive splenomegaly , 31% had a hematologic disorder, ... Splenomegaly . VIDEO: Chemo booster cuts treatment time by ... Splenomegaly . Definition: Splenomegaly is an enlargement of th...
...e than a trebling of risk of contralateral breast ... Specialty > Oncology > Breast Cancer ... Gynecologic Oncology Center. Center for hematologic Malignancies ... Urologic Oncology Center. Screening, Prevention and Early Detection. Technologies for Treatment ... ...
...t) mailing list ... The NCI PDQ patient statement on Myeloproliferative Disorders ... Myeloproliferative disorders , or MPD, are a group of hematologic (blood) ... Myeloproliferative Disorders (MPD) Advances in the Treatment in Myeloma ... The recent discovery of a key gene mutation has la...
...Department of Molecular Genetics & Microbiology ... All News and Articles> ... How Genzyme Can Help You Do More to Personalize TestingFor hematologic and solid tumor malignancies, Genzyme provides an Antibody Library, and a FISH Probe Library. ... ... to the Genetics Program at ... The inter...
...nthesis. ... Anemias in which the MCV is 80 to 100 femtoliters. Normocytic anemia is often ... Sideroblastic anemias also occur secondary to hematologic malignancies (eg, ... Anemias are caused by either excess red cell destruction, or underproduction of ... The megaloblastic anemias often pr...
... splenomegaly is usually defined as a spleen ex ... study evaluating splenomegaly in 2056 patients who ... massive splenomegaly , 31% had a hematologic disorder, ... Splenomegaly . VIDEO: Chemo booster cuts treatment time by ... Splenomegaly . Definition: Splenomegaly is an enlargement of th...
...e than a trebling of risk of contralateral breast ... Specialty > Oncology > Breast Cancer ... Gynecologic Oncology Center. Center for hematologic Malignancies ... Urologic Oncology Center. Screening, Prevention and Early Detection. Technologies for Treatment ... ...
...t) mailing list ... The NCI PDQ patient statement on Myeloproliferative Disorders ... Myeloproliferative disorders , or MPD, are a group of hematologic (blood) ... Myeloproliferative Disorders (MPD) Advances in the Treatment in Myeloma ... The recent discovery of a key gene mutation has la...
...Department of Molecular Genetics & Microbiology ... All News and Articles> ... How Genzyme Can Help You Do More to Personalize TestingFor hematologic and solid tumor malignancies, Genzyme provides an Antibody Library, and a FISH Probe Library. ... ... to the Genetics Program at ... The inter...
...nthesis. ... Anemias in which the MCV is 80 to 100 femtoliters. Normocytic anemia is often ... Sideroblastic anemias also occur secondary to hematologic malignancies (eg, ... Anemias are caused by either excess red cell destruction, or underproduction of ... The megaloblastic anemias often pr...
Hematologic in Biological News
Tumor-inhibiting protein could be effective in treating leukemia
...said. "We decided we wanted to look to see if Angiocidin had any effect on hematologic malignancy, and we chose leukemia." Tuszynski said leukemia cells arise ...a new therapeutic application for this protein, that it could differentiate hematologic malignancies into a normal-like state, allowing then for chemotherapy becau...Ireland Cancer Center researchers advance stem cell gene therapy
... this promising research, Ireland Cancer Center scientists presented 24 oral and poster presentations at ASH. The breadth and depth of this innovative hematologic research at the Ireland Cancer Center are outstanding, says Alvin Schmaier, MD, Chief of Hematology/Oncology at UHCMC and Case Western Reserve Univers...NCI renewal grant to develop new cancer therapies
... mode of action of these agents to make them even more effective in various hematologic malignancies by rationally combining them with other molecularly targeted a...easome and IKK beta inhibitors in the treatment of acute leukemia and other hematologic malignancies." Grant and his team are already leading a multi-institut...Daisies lead scientists down path to new leukemia drug
...ast progress in the drug development world, said Craig T. Jordan, Ph.D., senior author of the Blood article and director of Translational Research for hematologic Malignancies at the James P. Wilmot Cancer Center, at the University of Rochester Medical Center. Clinical trials are expected to begin in England ...UNC study questions FDA genetic-screening guidelines for cancer drug
.... The authors recommended that the FDA amend the product information for irinotecan to describe the association between irinotecan dose and risk of hematologic toxicity among patients with two UGT1A1*28 genes. ...Massey researchers induce cell death in leukemia
...ing body of preclinical and early clinical data suggesting interactions between HDAC inhibitors and bortezomib in other tumor cell types, particularly hematologic malignancies -- is certainly of interest and warrants further investigation as a potential therapeutic strategy in CLL." ...Knocking out survival protein could aid leukemia treatment
...effective target for drugs directed against CLL and ALL," says principal investigator John C. Byrd, professor of internal medicine and director of the hematologic malignancies program at Ohio State's James Cancer Hospital and Solove Research Institute. "These results give us a rationale for lowering the am...Customized gene chip provides rapid detection of genetic changes in children's cancer
...may help confirm a clinical diagnosis, said Saul Surrey, Ph.D., professor of medicine and Associate Director of Research at the Cardeza Foundation for hematologic Research and the Division of Hematology at Jefferson Medical College. If a clinical diagnosis isn't known, the method might provide some clues. The...Leukemia Drug Breakthrough Study In New England Journal Of Medicine
... Alan List, M.D., leader of the hematologic Malignancies Program at the H. Lee Moffitt Cancer Center & Research Institute, recently conducted a phase I/II trial of the experimental drug Revl...Hematologic in Biological Technology
...Multiple Myeloma
Multiple myeloma, a cancer of the plasma cell, is an incurable but treatable disease. Multiple myeloma is the second most-common hematologic cancer, representing 1% of all cancer diagnoses and 2% of all cancer deaths. According to the American Cancer Society, in 2009, there will be an estim...
...ally lower (13 per cent vs. 25 per cent) Elacytarabine is a novel cytotoxic agent being developed by Clavis Pharma for the treatment of hematologic cancers and solid tumors, especially those resistant to existing agents. One particularly difficult-to-treat patient group is late-stage acute myeloid...
...ble proteasome inhibitors being developed by Proteolix for the treatment of hematologic malignancies and solid tumors. Relapsed Multiple Myeloma Patients A...se 2 clinical trials, carfilzomib has demonstrated single-agent activity in hematologic malignancies and solid tumors, including multiple myeloma, Waldenstrom's ma...
...e.g., persistent fever, bruising, bleeding, pallor) while on CIMZIA. Consider discontinuation of CIMZIA therapy in patients with confirmed significant hematologic abnormalities. An increased risk of serious infections has been seen in clinical trials of other TNF blocking agents used in combination with an...
...t ovarian cancer or AIDS-related Kaposi's sarcoma, hematologic toxicity (based on platelet count or absolute neut...IL In patients with multiple myeloma, hematologic toxicity (based on platelet count, absolute neutro...toxicity of other anticancer therapies, especially hematologic toxicities, when used in combination with other th...
...and services. "As a leader in diagnostics for hematologic cancers, we believe our studies will help investig...ble to doctors for directly identifying markers of hematologic cancers in blood plasma rather than painfully extr...id tumors, such as prostate cancer, as well as for hematologic cancers. In addition, in February 2009, the compan...
Sunesis Receives Approval for Listing on The NASDAQ Capital Market
...mmercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that NASDAQ has approved its application to transf...mmercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development org...Sunesis Reports Financial Results for the Second Quarter 2009
... Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in ......ally lower (13 per cent vs. 25 per cent) Elacytarabine is a novel cytotoxic agent being developed by Clavis Pharma for the treatment of hematologic cancers and solid tumors, especially those resistant to existing agents. One particularly difficult-to-treat patient group is late-stage acute myeloid...
Sunesis to Present at the Jefferies 3rd Annual Healthcare Conference
...mmercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that Daniel Swisher, Chief Executive Officer of Su...mmercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development org......ble proteasome inhibitors being developed by Proteolix for the treatment of hematologic malignancies and solid tumors. Relapsed Multiple Myeloma Patients A...se 2 clinical trials, carfilzomib has demonstrated single-agent activity in hematologic malignancies and solid tumors, including multiple myeloma, Waldenstrom's ma...
...e.g., persistent fever, bruising, bleeding, pallor) while on CIMZIA. Consider discontinuation of CIMZIA therapy in patients with confirmed significant hematologic abnormalities. An increased risk of serious infections has been seen in clinical trials of other TNF blocking agents used in combination with an...
...t ovarian cancer or AIDS-related Kaposi's sarcoma, hematologic toxicity (based on platelet count or absolute neut...IL In patients with multiple myeloma, hematologic toxicity (based on platelet count, absolute neutro...toxicity of other anticancer therapies, especially hematologic toxicities, when used in combination with other th...
...and services. "As a leader in diagnostics for hematologic cancers, we believe our studies will help investig...ble to doctors for directly identifying markers of hematologic cancers in blood plasma rather than painfully extr...id tumors, such as prostate cancer, as well as for hematologic cancers. In addition, in February 2009, the compan...
Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting
...ptosis in cancer cells with minimal off-target effects. In Phase 1 and Phase 2 clinical trials, carfilzomib has demonstrated single-agent activity in hematologic malignancies and solid tumors, including multiple myeloma, Waldenstrom's macroglobulinemia, mantle cell lymphoma, and renal cell carcinoma. Pro...Other TagsOther Contents
QuestionableMediInflictCourtesycalendarbuttLaudedcomplimentsPrawnsCultConfessesPericarditiBraxtonNearest
(Date:5/21/2013)... TX (PRWEB) May 21, 2013 Medical ... with the prestigious 2013 Top-Rated Award by GreatNonprofits , ... “We are excited to be named a Top-Rated 2013 Nonprofit,” ... without the dedication of our over 3000 Volunteers and Staff ... especially significant as it came from those that have seen ...
(Date:5/21/2013)... analogues (PGAs), drugs which lower intraocular pressure, are often ... but their use is not without risks. PGAs have ... eye color and other side effects. Now a new ... and lower eyelid drooping and other issues that can ... PLOS ONE . , Researchers from the Massachusetts Eye ...
(Date:5/21/2013)... Beach, CA (PRWEB) May 21, 2013 ... 3rd Annual EB-5 Investment Summit: Dealmakers Conference in ... Dealmakers Conference will focus on exploring alternative finance ... provide the latest market, legal and economic information, ... immigration and legal professionals within the EB-5 industry. ...
(Date:5/21/2013)... 2013 The federal judge overseeing the ... lawsuits in U.S. District Court, Northern District of ... request from Plaintiffs’ Counsel to conduct Ex Parte interviews ... 17th Order grants that request, and sets forth procedures ... Wright Medical Technology, Inc., Conserve Hip Implant Products Liability ...
(Date:5/21/2013)... 2013 MedMar Healing Center announces ... Second Harvest Food Bank. Twenty-eight businesses, including MedMar Healing Center, ... food drive. The goal is to raise food to help ... facing their families in recent years. , “We like ... those in need,” explains Douglas Chloupek of MedMar Healing Center. ...
Breaking Medicine News(10 mins):Health News:Medical Ministry International Recognized as a 2013 Top-rated Nonprofit By GreatNonprofits.org 2Health News:Glaucoma drug can cause droopy eyelids 2Health News:Artisan Business Group to Host EB-5 Investment Conference in Long Beach, California 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2[0] Medical Ministry International Recognized as a 2013 Top-rated Nonprofit By GreatNonprofits.org[0] Glaucoma drug can cause droopy eyelids[0] Artisan Business Group to Host EB-5 Investment Conference in Long Beach, California[0] Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation[0] San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank
(Date:5/21/2013)... at USC have found that a class of pharmaceuticals ... , The drugs, known as "TSPO ligands," are ... looked at the effects of TSPO ligand in young ... and in aged mice when pathology was quite severe," ... School of Gerontology. "TSPO ligand reduced measures of pathology ...
(Date:5/21/2013)... of Illinois at Chicago College of Medicine will study gender ... its main energy source -- and how changes in fat ... $2 million, 4-year grant from the National Heart, Lung and ... uses fuel for energy. These changes may play a major ... in men and women, says E. Douglas Lewandowski, director of ...
(Date:5/21/2013)... path of insulin action in cells in precise detail ... understanding what goes wrong in diabetes. , The ... James from Sydney,s Garvan Institute of Medical Research, is ... prestigious journal Cell Metabolism . , First discovered ... role in the body because it helps us lower ...
Breaking Biology News(10 mins):Drugs found to both prevent and treat Alzheimer's disease in mice 2Do men's and women's hearts burn fuel differently? 2Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |